Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 16, 2017 08:45 ET | Source: Photocure ASA

Photocure ASA: Presentation of the second quarter and first half year 2017 results

Photocure will present its second quarter and first half year report on Wednesday 23 August 2017 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives...
August 16, 2017 01:31 ET | Source: Photocure ASA

Photocure files supplemental New Drug Application with FDA for Blue Light Cystoscopy (BLC(TM)) with Cysview®

Oslo, Norway, August 16th Photocure ASA (OSE: PHO) announced today that it has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) for BLC(TM) with...
July 31, 2017 05:39 ET | Source: Photocure ASA

Photocure ASA: First European study to show that Blue Light Flexible Cystoscopy with Hexvix® can replace conventional follow up of CIS patients

Oslo, Norway, July 31, 2017: Photocure ASA (OSE: PHO) today announced that a study investigating the use of Blue Light Flexible Cystoscopy with Hexvix® (BLFC(TM)) in patients with Carcinoma in Situ...
July 17, 2017 02:00 ET | Source: Photocure ASA

Photocure ASA : UPDATE ON MEDICARE REIMBURSEMENT FOR BLUE LIGHT CYSTOSCOPY WITH CYSVIEW®

Oslo, Norway, July 17, 2017: Photocure ASA (OSE: PHO), announced today that the United States Centers for Medicare & Medicaid Services (CMS) has released the Proposed Rule outlining its 2018...
May 23, 2017 01:04 ET | Source: Photocure ASA

Photocure ASA: Results for the first quarter of 2017

Oslo, Norway, 23 May 2017: Photocure ASA (OSE: PHO) today reported a Hexvix/Cysview revenue growth of 9% to NOK 36.5 million in the first quarter of 2017 (Q1 2016: NOK 33.5), with an EBITDA of NOK...
May 16, 2017 08:53 ET | Source: Photocure ASA

Photocure ASA: Presentation of the first quarter 2017 results and the results from the Blue Light Flexible Cystoscopy with Hexvix®/Cysview® phase 3 study

Photocure will present its first quarter report on Tuesday 23 May 2017 at Hotel Continental, Oslo, Norway. Additionally, Dr. Daneshmand will present the new phase 3 study results with Blue Light...
May 15, 2017 02:30 ET | Source: Photocure ASA

Photocure ASA: Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 meeting in Boston

21.5% of patients with recurrence of bladder cancer would have been missed if BLFC with Cysview had not been used in the surveillance setting, which is highly significant (p<0.0001) ...
May 12, 2017 02:29 ET | Source: Photocure ASA

Photocure ASA: Phase 3 study investigating Blue Light Flexible Cystoscopy with Cysview® in surveillance setting meets primary endpoint

Oslo, Norway, May 12th, 2017: Photocure ASA (Photocure, PHO:OSE), today announced that a Phase 3 trial investigating Blue Light Flexible Cystoscopy (BLFC(TM)) with Cysview®/Hexvix® in the...
May 05, 2017 02:00 ET | Source: Photocure ASA

Jeremy Bahr appointed Chief Business Officer

Oslo, Norway, May 5 2017: Photocure ASA (OSE:PHO), today announced the appointment of Jeremy Bahr as Chief Business Officer. "I am pleased to welcome Jeremy to the Photocure team, strengthening our...
April 28, 2017 02:00 ET | Source: Photocure ASA

Photocure Appoints Three New Members to its Board of Directors

Dr. Jan Hendrik Egberts - Board ChairmanDr. Johanna HolldackMs. Gwen Melincoff Oslo, Norway April, 28, 2017: Photocure ASA (OSE:PHO), a specialty pharmaceutical company and world leader in...